AstraZeneca (AZN) Upgraded at JPMorgan Chase & Co.

JPMorgan Chase & Co. upgraded shares of AstraZeneca (NYSE:AZN) from a neutral rating to an overweight rating in a research report report published on Friday, MarketBeat reports.

Several other brokerages also recently weighed in on AZN. Citigroup upgraded AstraZeneca to a buy rating in a research note on Wednesday, October 18th. Cowen restated a hold rating and set a $37.00 target price on shares of AstraZeneca in a research note on Tuesday, October 17th. Leerink Swann increased their target price on AstraZeneca from $31.00 to $34.00 and gave the company a market perform rating in a research note on Monday, October 23rd. Credit Suisse Group upgraded AstraZeneca from a neutral rating to an outperform rating in a research note on Monday, October 16th. Finally, BMO Capital Markets set a $38.00 target price on AstraZeneca and gave the company a buy rating in a research note on Tuesday, October 31st. Four investment analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have issued a buy rating to the stock. AstraZeneca currently has a consensus rating of Hold and an average target price of $34.20.

Shares of AstraZeneca (NYSE AZN) opened at $34.70 on Friday. AstraZeneca has a 52 week low of $26.51 and a 52 week high of $35.60. The firm has a market capitalization of $87,859.08, a P/E ratio of 12.44, a P/E/G ratio of 3.16 and a beta of 0.72. The company has a debt-to-equity ratio of 1.09, a quick ratio of 0.72 and a current ratio of 0.94.

AstraZeneca (NYSE:AZN) last announced its earnings results on Thursday, November 9th. The company reported $1.12 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.55. AstraZeneca had a return on equity of 34.02% and a net margin of 15.90%. The firm had revenue of $6.23 billion during the quarter, compared to the consensus estimate of $6 billion. During the same quarter in the prior year, the company earned $1.32 EPS. The firm’s revenue for the quarter was up 9.4% compared to the same quarter last year. equities analysts forecast that AstraZeneca will post 1.87 earnings per share for the current year.

A number of institutional investors have recently bought and sold shares of the business. Parametric Portfolio Associates LLC raised its holdings in AstraZeneca by 11.6% in the 3rd quarter. Parametric Portfolio Associates LLC now owns 1,790,092 shares of the company’s stock valued at $60,648,000 after acquiring an additional 186,457 shares in the last quarter. Steward Partners Investment Advisory LLC acquired a new position in AstraZeneca in the 3rd quarter valued at approximately $478,000. Belpointe Asset Management LLC acquired a new position in AstraZeneca in the 3rd quarter valued at approximately $309,000. Wealthcare Advisory Partners LLC acquired a new position in AstraZeneca in the 3rd quarter valued at approximately $184,000. Finally, Sterling Capital Management LLC acquired a new position in AstraZeneca in the 3rd quarter valued at approximately $248,000. 14.75% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “AstraZeneca (AZN) Upgraded at JPMorgan Chase & Co.” was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.chaffeybreeze.com/2018/01/01/astrazeneca-azn-upgraded-at-jpmorgan-chase-co.html.

About AstraZeneca

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply